טוען...
Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
Background/Aim: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. Patients and Methods: Twelve patients with R/M-NPC were...
שמור ב:
| הוצא לאור ב: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
International Institute of Anticancer Research
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7652473/ https://ncbi.nlm.nih.gov/pubmed/32871839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12127 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|